COPENHAGEN, Denmark (AFP) — Danish pharmaceuticals group Novo Nordisk, the world’s leading insulin maker, said Wednesday it is raising its full-year profit targets after sales of its anti-obesity and diabetics treatments boosted its bottom line in the third quarter. Novo Nordisk said in a statement that net profit rose by 18 percent to 12.119 billion kroner (1.6 billion euros, $1.9 billion) in the period from July to September on a 15-precent increase in sales to […]